5-Aminolaevulinic Acid–Induced Fluorescence in Primary Central Nervous System Lymphoma
- 1 February 2017
- journal article
- research article
- Published by Elsevier in World Neurosurgery
- Vol. 98, 375-380
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Lamin A/C cleavage by caspase-6 activation is crucial for apoptotic induction by photodynamic therapy with hexaminolevulinate in human B-cell lymphoma cellsCancer Letters, 2013
- CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphomaBlood, 2013
- Gefitinib enhances the efficacy of photodynamic therapy using 5-aminolevulinic acid in malignant brain tumor cellsPhotodiagnosis and Photodynamic Therapy, 2013
- 5-Aminolevulinic acid (5-ALA)-induced fluorescence in intracerebral metastases: a retrospective studyActa Neurochirurgica, 2011
- Age, gender, and racial differences in incidence and survival in primary CNS lymphomaBritish Journal of Cancer, 2011
- Silencing of ferrochelatase enhances 5-aminolevulinic acid-based fluorescence and photodynamic therapy efficacyBritish Journal of Cancer, 2011
- Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatmentLeukemia & Lymphoma, 2008
- 5-Aminolevulinic acid-based photodynamic therapy suppressed survival factors and activated proteases for apoptosis in human glioblastoma U87MG cellsNeuroscience Letters, 2007
- Photodynamic therapy and anti-tumour immunityNature Reviews Cancer, 2006
- Surgical removal of primary central nervous system lymphomas (PCNSL) presenting as space occupying lesions: a series of 33 casesEuropean Journal of Surgical Oncology, 2005